Comparison of the Luminex xTAG respiratory viral panel with in-house nucleic acid amplification tests for diagnosis of respiratory virus infections
Comparison of the Luminex xTAG respiratory viral panel with in-house nucleic acid amplification tests for diagnosis of respiratory virus infections
复制标题
DOI：
10.1128/jcm.00878-08
复制
发表时间：
2008-09-01
影响因子：
9.4
通讯作者：
Fox, Julie D.
中科院分区：
文献类型：
--
作者：
Pabbaraju, Kanti;Tokaryk, Kara L.;Fox, Julie D.
使用灵敏的实时核酸扩增检测（NAT）检测呼吸道病毒对于患者和疫情管理非常重要。然而，广泛的潜在呼吸道病毒病原体使得使用单个实时NAT进行测试昂贵且费力。本研究的目的是比较使用Luminex xTAG呼吸道病毒检测试剂盒（RVP）检测与加拿大阿尔伯塔卡尔加里省公共卫生实验室使用的单个实时NAT检测呼吸道病毒靶标。该研究包括2006年12月至2007年5月期间提交用于诊断呼吸道感染的1，530份样本。直接荧光抗原阳性鼻咽样本从本研究中排除。RVP和内部NAT分别检测到690和643例阳性。所有靶标的内部NAT与RVP之间的Kappa相关性范围为0.721至1.000。内部NAT遗漏的大多数标本（96.7%）为小核糖核酸病毒阳性。RVP漏诊的样本主要为腺病毒（51.7%）或呼吸道合胞病毒（27.5%）阳性（内部NAT），通常病毒载量较低。与替代NAT相比，RVP允许多重检测20种（并区分19种）呼吸道病毒靶标，节省了大量时间和成本。尽管该第一版RVP检测试剂盒检测腺病毒的灵敏度低于内部NAT，但其对其他靶标具有良好的灵敏度。通过RVP识别小核糖核酸病毒和冠状病毒以及同时对甲型流感病毒进行分型（目前未包括在我们的诊断检测算法中）将改善我们对呼吸道感染的诊断。
Detection of respiratory viruses using sensitive real-time nucleic acid amplification tests (NATs) is invaluable for patient and outbreak management. However, the wide range of potential respiratory virus pathogens makes testing using individual real-time NATs expensive and laborious. The objective of this study was to compare the detection of respiratory virus targets using the Luminex xTAG respiratory viral panel (RVP) assay with individual real-time NATs used at the Provincial Laboratory of Public Health, Calgary, Alberta, Canada. The study included 1,530 specimens submitted for diagnosis of respiratory infections from December 2006 to May 2007. Direct-fluorescent-antigen-positive nasopharyngeal samples were excluded from this study. A total of 690 and 643 positives were detected by RVP and in-house NATs, respectively. Kappa correlation between in-house NATs and RVP for all targets ranged from 0.721 to 1.000. The majority of specimens missed by in-house NATs (96.7%) were positive for picornaviruses. Samples missed by RVP were mainly positive for adenovirus (51.7%) or respiratory syncytial virus (27.5%) by in-house NATs and in general had low viral loads. RVP allows for multiplex detection of 20 (and differentiation between 19) respiratory virus targets with considerable time and cost savings compared with alternative NATs. Although this first version of the RVP assay has lower sensitivity than in-house NATs for detection of adenovirus, it has good sensitivity for other targets. The identification of picornaviruses and coronaviruses and concurrent typing of influenza A virus by RVP, which are not currently included in our diagnostic testing algorithm, will improve our diagnosis of respiratory tract infections.